Order Article Reprints

Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C, Candiota AP. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals. 2017; 10(1):24. https://doi.org/10.3390/ph10010024

Ferrer-Font, Laura, Lucia Villamañan, Nuria Arias-Ramos, Jordi Vilardell, Maria Plana, Maria Ruzzene, Lorenzo A. Pinna, Emilio Itarte, Carles Arús, and Ana Paula Candiota. 2017. "Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice" Pharmaceuticals 10, no. 1: 24. https://doi.org/10.3390/ph10010024

Ferrer-Font, L., Villamañan, L., Arias-Ramos, N., Vilardell, J., Plana, M., Ruzzene, M., Pinna, L. A., Itarte, E., Arús, C., & Candiota, A. P. (2017). Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals, 10(1), 24. https://doi.org/10.3390/ph10010024